Department of Dermatology, University of California, San Francisco2Department of Pathology, University of California, San Francisco.
Department of Dermatology, University of California, San Francisco3Dermatology Research Unit, San Francisco Veterans Affairs Medical Center, San Francisco, California.
JAMA Dermatol. 2016 Mar;152(3):323-7. doi: 10.1001/jamadermatol.2015.4233.
Multiple hereditary infundibulocystic basal cell carcinoma syndrome (MHIBCC) is a rare genodermatosis in which numerous indolent, well-differentiated basal cell carcinomas develop primarily on the face and genitals, without other features characteristic of basal cell nevus syndrome. The cause is unknown. The purpose of the study was to identify a genetic basis for the syndrome and a mechanism by which the associated tumors develop.
Whole-exome sequencing of 5 tumors and a normal buccal mucosal sample from a patient with MHIBCC was performed. A conserved splice-site mutation in 1 copy of the suppressor of fused gene (SUFU) was identified in all tumor and normal tissue samples. Additional distinct deletions of the trans SUFU allele were identified in all tumor samples, none of which were present in the normal sample.
A germline SUFU mutation was present in a patient with MHIBCC, and additional acquired SUFU mutations underlie the development of infundibulocystic basal cell carcinomas. The downstream location of the SUFU gene within the sonic hedgehog pathway may explain why its loss is associated with relatively well-differentiated tumors and suggests that MHIBCC will not respond to therapeutic strategies, such as smoothened inhibitors, that target upstream components of this pathway.
多发性遗传性漏斗囊状基底细胞癌综合征 (MHIBCC) 是一种罕见的皮肤遗传病,主要发生在面部和生殖器上,存在许多惰性、分化良好的基底细胞癌,而没有基底细胞痣综合征的其他特征。其病因未知。本研究的目的是确定该综合征的遗传基础以及相关肿瘤发生的机制。
对 1 例 MHIBCC 患者的 5 个肿瘤和正常颊黏膜样本进行了全外显子组测序。在所有肿瘤和正常组织样本中均发现了 1 个 SUFU 基因的保守剪接位点突变。在所有肿瘤样本中还发现了转 SUFU 等位基因的额外独特缺失,但在正常样本中均不存在。
MHIBCC 患者存在种系 SUFU 突变,并且额外获得的 SUFU 突变是漏斗囊状基底细胞癌发展的基础。SUFU 基因在 sonic hedgehog 通路中的下游位置可能解释了其缺失与相对分化良好的肿瘤相关的原因,并表明 MHIBCC 不会对靶向该通路上游成分的治疗策略(如 smoothened 抑制剂)产生反应。